Q1 2025 Earnings Summary
Metric | YoY Change | Reason |
---|---|---|
Total Revenue | +2.3% (from $13.617M in Q1 2024 to $13.919M in Q1 2025) | Modest revenue growth driven by underlying stability in both the Treatment and Services segments, maintaining similar contribution levels to prior periods. |
Gross Profit | Improved by ~$1.277M (from -$620K in Q1 2024 to +$657K in Q1 2025) | Reversal of last year's margin weakness due to improved cost management and operational performance across segments, overcoming the negative margin experienced in the previous year. |
Operating Loss | Narrowed by ~16% (from -$4,460K in Q1 2024 to -$3,736K in Q1 2025) | Improved operating performance stemming from tighter cost control initiatives and better project execution compared to the prior period, leading to a smaller operating loss. |
R&D Expenses | Increased by nearly 29% (from $296K in Q1 2024 to $383K in Q1 2025) | A more aggressive investment in innovation reflects a strategic shift; the company is allocating additional funds to R&D relative to the previous period to fuel future growth. |
Operating Cash Flow | Losses reduced by about 54% (from -$4,591K in Q1 2024 to -$2,104K in Q1 2025) | Significant improvement in cash flow efficiency was achieved through better operational management and expense controls, markedly reducing the negative cash flow compared to the prior period. |
Cash | Declined ~11% (from $28,975K in Q4 2024 to $25,745K in Q1 2025) | An 11% drop in cash suggests increased cash deployment for operations or investments compared to the previous period, even though overall current assets remain healthy. |